Taiwan Sugar Corporation

Total investments

1

Average round size

37M

Portfolio companies

1

Rounds per year

0.01

Exits

1

Areas of investment
BiotechnologyHealth CarePharmaceutical

Summary

Taiwan Sugar Corporation appeared to be the Corporate Investor, which was created in 1946.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2009.

Among the various public portfolio startups of the fund, we may underline TaiGen Biotechnology Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Pharmaceutical.

The usual cause for the fund is to invest in rounds with 5 partakers. Despite the Taiwan Sugar Corporation, startups are often financed by YFY Inc., Shin Kong Life Insurance, Major Series A. The meaningful sponsors for the fund in investment in the same round are YFY Inc., YFY Biotech Management Company, National Development Fund of Taiwan Government.

Show more

Investments analytics

Analytics

Total investments
1
Lead investments
0
Exits
1
Rounds per year
0.01
Investments by industry
  • Biotechnology (1)
  • Pharmaceutical (1)
  • Health Care (1)
Investments by region
  • Taiwan (1)
Peak activity year
2009

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
20
Group Appearance index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
TaiGen Biotechnology 01 Jan 2009 Biotechnology, Health Care, Pharmaceutical Late Stage Venture 37M New Taipei, Taiwan
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.